TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced measurable or non-measurable solid tumors~* Adequate bone marrow function~* Adequate liver function~* Adequate renal function~* Be able and willing to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures~Exclusion Criteria:~* Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of first dose of study medication~* Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, hemoptysis or melena in the past 6 months~* Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus; or any other active thromboembolic event~* QTc prolongation defined as QTc \>450 msec~* Patients with known brain metastasis~* Patients with peritoneal carcinosis at risk of bleeding~* Major surgical procedure within 4 weeks of treatment~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has bilateral chronic sinusitis confirmed by CT scan and defined as inflammation of the mucosa of the nose and paranasal sinuses of at least 8 consecutive weeks' duration.~* Patient is indicated for and has consented to FESS.~* FESS successfully completed without significant complication that in the opinion of the physician would confound study results and the patient's anatomy remains amenable to Sinus Stent placement.~CT Imaging Inclusion Criteria:~* CS diagnosis confirmed and documented by CT Scan within 6 months of the procedure.~* Patient has minimum total CT score (Lund-Mackay method) of 6. • Patient has bilateral ethmoid sinus disease confirmed by CT.~Exclusion Criteria:~* insulin dependent diabetics~* oral steroid dependent condition~* glaucoma, ocular hypertension, posterior subcapsular cataracts~* middle turbinate resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Coated (Type: ACTIVE_COMPARATOR): Sinus stent coated with steroid
- Non coated (Type: PLACEBO_COMPARATOR): Sinus stent without drug coating

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe low back pain for ≥6 months~* Treating CLBP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥30 mg and ≤160 mg morphine sulfate equivalents (MSE) per day for ≥4 weeks. (Additional as needed \[PRN\] analgesic rescue medications permitted on top of the stable daily maintenance dose of ≥30 mg MSE opioid analgesic, but must be included in the total daily MSE calculation and in combination with the stable daily maintenance dose not to exceed 160 mg MSE per day)~* Stable health, as determine by Principal Investigator~* Females are practicing abstinence, using a medically acceptable form of contraception, or post-menopausal, biologically sterile, or surgically sterile for more than 1 year~* Willing and able to comply with all protocol required visits and assessments~Exclusion Criteria:~* Current cancer related pain or received chemotherapy within 6 months of screening~* Subjects with history of other chronic painful conditions~* Reflex sympathetic dystrophy or causalgia, acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis~* Allergy or contraindications of any opioid or acetaminophen~* Surgical procedure for relief of pain within 6 months~* Hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia~* QT interval corrected using Fridericia's formula (QTcF) of ≥450 milliseconds on the 12-lead electrocardiogram (ECG)~* History of long QT syndrome or a family member with this condition~* Moderate to severe hepatic impairment~* Moderate to severe renal impairment~* Current or past history of alcohol abuse~* Positive urine toxicology screen for drug of abuse~* History or abnormalities on physical exam, vital signs, electrocardiogram, or laboratory values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Buccal Film (Type: PLACEBO_COMPARATOR): Twice Daily Dosing
- Buprenorphine HCl Buccal Film (Type: EXPERIMENTAL): Twice Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lung Ultrasound in PD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years old,~* History of PD more than 3 months,~* Providing written informed consent~Exclusion Criteria:~* Patients younger than 18 years old,~* Unwilling to participate to the study,~* Immobile patients unable to perform test in the same day,~* History of PD less than 3 months,~* Presence of active infection,~* History of lung cancer and/or operations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- PD patients (Type: None): All PD patients treated in out unit were enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with PAH who had completed the 12 week pivotal study~Exclusion Criteria:~* Any other patients with PAH that had not been included into the pivotal study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* Current treatment: oral anti-diabetic drug(s) (OAD(s)) alone, basal insulin alone or the combination of OAD(s) and basal insulin. Allowed OADs are: Metformin, insulin secretagogues (sulphonylureas (SU) or glinides), pioglitazone with unchanged dosing for at least 3 months prior to Visit 1~* HbA1c: OADs only users 7.0-11.0 % (both inclusive), basal insulin with/without OADs users 7.0-10.0% (both inclusive) by central laboratory analysis~* Body Mass Index (BMI) below or equal to 40.0 kg/m\^2~Exclusion Criteria:~* Cancer and medical history of cancer hereof~* Use within the last 3 months prior to Visit 1 of: glucagon-like peptide-1(GLP-1) receptor agonist (exenatide, liraglutide), rosiglitazone, dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase-inhibitors~* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer hereof (except basal cell skin cancer and squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD FF (Type: EXPERIMENTAL): None
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The General Use of Robots in Stroke Recovery: the Anklebot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* First single focal unilateral lesion with diagnosis verified by brain imaging, which occurred at least 6 months prior~* Cognitive function sufficient enough to understand experiments and follow instructions~* Some amount of independent ambulation (with orthoses or walker)~Exclusion Criteria:~* Botox treatment within 6-weeks of enrollment;~* Fixed contraction deformity in the affected limb;~* Complete and total flaccid paralysis of all lower extremity motor function;~* Unable to ambulate except with the aid of another person

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- seated robot-assisted ankle therapy (Type: EXPERIMENTAL): All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (\<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (\>0.8m/sec) functioning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can we Use Intravenous Injection of Tranexamic Acid in Routine Practice With Active Management of the Third Stage of Labor?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age between 37 and 42 weeks,~* live fetus,~* cephalic presentation,~* vaginal birth.~* Patients who had a risk factors for PPH, such as multiple gestation, polyhydramnios, fetal macrosomia, antepartum hemorrhage, anemia (haemoglobin concentration \< 8 g/dL), severe pre-eclampsia, or coagulopathy~Exclusion Criteria:~* placenta previa,~* placental abruption,~* cesarean section or any uterine scar, abnormal placentation (accreta, increta, or percreta),~* a current or previous history of significant disease, including heart disease, liver, renal disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- tranexamic acid (Type: ACTIVE_COMPARATOR): TA administered intravenously over a 5 min period at delivery of the anterior shoulder
- saline (Type: NO_INTERVENTION): 10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute coronary syndromes~* Pretreatment (2 hours) with high loading dose (600 mg) clopidogrel~* Significant angiographic lesions amenable to and requiring a PCI~* Written informed consent~Exclusion Criteria:~* ST-segment elevation acute myocardial infarction within 48 hours from symptom onset~* Hemodynamic instability~* Pericarditis~* Malignancies with life expectancy less than one year~* Increased risk of bleeding~* Oral anticoagulation therapy with coumarin derivative within 7 days~* Recent use of GPIIb/IIIa inhibitors within 14 days~* Severe uncontrolled hypertension \>180 mmHg unresponsive to therapy~* Relevant hematologic deviations: hemoglobin \< 100g/L or hematocrit \< 34%; platelet count \< 100 x 10\^9/L or platelet count \> 600 x 10\^9/L.~* Known allergy to the study medication~* Pregnancy (present or suspected)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria in the open-label phase:~* Outpatients~* Men and women 18 to 75 years of age, inclusive. Sexually active women participating in the study must use a medically acceptable form of contraception (Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception)~* Subjects must have a primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), single or recurrent episode, without psychotic features (If other allowable psychiatric diagnoses are present, MDD must be the predominant psychiatric disorder present.)~Exclusion Criteria:~* Treatment with DVS-233 SR at any time in the past~* Treatment with venlafaxine (immediate release \[IR\] or ER) within 90 days of study day 1~* Known hypersensitivity to venlafaxine (IR or ER)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PSC Diagnosis: Liver biopsy and/or imaging (MRCP, ERCP, CT, or US~* Colonoscopy within 1 year or starting of study~* 2 groups:~  1. IBD (Inflammatory bowel disease) and PSC: details of extent and type of IBD~ 2. No IBD and PSC, but positive p-ANCA or ASCA serologies indicating possible IBD.~Exclusion Criteria:~* Allergy to Vancomycin~* PSC not associated with IBD or NO positive IBD antibodies (p-ANCA \[anti- neutrophil cytoplasmic antibody\] or ASCA \[anti-Saccharomyces cerevisiae antibody\])~* Cholangiocarcinoma~* On oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or biologics (infliximab, adalimumab, certolizumab).

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Oral Vancomycin (Type: EXPERIMENTAL): 1) For children who weight \< or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh \>30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the prostate with radiographic evidence of metastatic disease.~* Willingness to undergo a baseline tumor biopsy.~* Castrate levels of testosterone (testosterone \< 50 ng/dL) on androgen deprivation therapy (ADT) with evidence of progression on ADT. GnRH therapy will be continued for those on it at baseline~* Patient must have suspected tumor in an area that is safe to biopsy.~* Other prior hormonal interventions or experimental approaches are allowed. These therapies must have been discontinued for a minimum of 28 days with cancer progression.~* Prior or concurrent use of bisphosphonates is allowed.~* One prior non-taxane chemotherapy allowed~* ≥ 3 weeks since major surgery; ≥ 4 weeks since radiotherapy; ≥ 8 weeks since prior strontium-89 or samarium 153~* Performance Status: ECOG 0 or 1~* ANC \> 1,500/_l; platelets \> 100,000/_l; total Bilirubin \< upper limit of normal; AST and ALT \< 3 x upper limits of normal; creatinine \< 1.5 x upper limits of normal; total fasting cholesterol \< 350 mg/dl; total triglycerides \< 300 mg/dl~Exclusion Criteria:~* Ongoing oral steroid use. Patients with a history of oral steroid use are eligible as long as the steroids have been discontinued prior to study entry. Ongoing topical and/or inhaled steroid use is allowed.~* Prior taxane chemotherapy~* Prior mTOR inhibitors (RAD001, rapamycin, CCI-779)~* Currently active second malignancy other than non-melanoma skin cancer.~* Ongoing peripheral neuropathy of Grade 2

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 Followed by RAD001 + Docetaxel (Type: EXPERIMENTAL): RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Dexmedetomidine Premedication in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children older than 5yrs and weighing more than 20kg , who are scheduled for ambulatory dental rehabilitation at Batson operating rooms.~* ASA classification 1 or 2~Exclusion Criteria~* Known allergy to midazolam, dexmedetomidine,morphine, fentanyl, sevoflurane and propofol.~* uncorrected congenital heart disease or history of cardiac arrhythmia,~* children at risk for airway obstruction (OSA or cranio facial syndrome),~* pregnant minors

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
- Dexmedetomidine (Type: EXPERIMENTAL): In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete